QT
NRXP icon

Quantbot Technologies’s NRX Pharmaceuticals NRXP Stock Holding History

Quantbot Technologies’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-170
Closed -$8K – 1930
2021
Q4 		$8K Buy
170
+13
+8% +$938 ﹤0.01% 1339
2021
Q3 		$14K Buy
+157
New +$20.4K ﹤0.01% 1315

Other funds holding NRXP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Quantbot Technologies's NRXP Position: Q1 2022 in Review

Quantbot Technologies sold out of NRX Pharmaceuticals (NRXP) in Q1 2022, closing a stake of 170 shares — an estimated $8K sold.

Quantbot Technologies first reported a position in NRXP in Q3 2021 and held it in 2 quarters. The position peaked at $14K in Q3 2021. 34 funds tracked by Wall St. Rank hold NRXP as of Q1 2022.

  • Quantbot Technologies reported no remaining NRX Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Quantbot Technologies sold 170 NRX Pharmaceuticals shares in Q1 2022, an estimated $8K.
  • Quantbot Technologies first reported a position in NRX Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Quantbot Technologies's NRX Pharmaceuticals position peaked at $14K in Q3 2021.
  • 34 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2022.

Based on Quantbot Technologies's 13F filing for Q1 2022, filed 16 May 2022.